Lybrel new birth control pill

The U.S. Food and Drug Administration is expect to announce approval for Lybrel, non-cyclic combination oral contraceptive.
Lybrel would be the fourth after Yaz, Loestrin 24, and Seasonique new version of Seasonale new oral contraceptive that doesn’t follow the standard schedule of 21 daily active pills, followed by seven sugar pills.
Lybrel contains the lowest dose of two hormones widely used in birth-control pills, ethinyl estradiol and levonorgestrel.

Low hormone doses might cause too much breakthrough bleeding.
In testing of Lybrel, 59 percent of women ended up with no bleeding after six months, but 18 percent of women dropped out of studies because of spotting and breakthrough bleeding.